comprehensive -WSS

comprehensive

author：leisure time 2025-09-28 23:49:49 - browse：99

Aduhelm package — Jessica Rinaldi/The Boston Globe

Biogen is giving up its ownership of Aduhelm, the Alzheimer’s disease treatment whose 2021 approval led to scrutiny and outrage, turning the page on a tempestuous chapter in the company’s long history.

Neurimmune, the Swiss company that invented Aduhelm, will regain full rights to the intravenous medicine, Biogen said Wednesday. Biogen will also terminate an ongoing clinical trial meant to prove the treatment’s benefits for patients in the early stages of Alzheimer’s.

“When searching for new medicines, one breakthrough can be the foundation that triggers future medicines to be developed,” Biogen CEO Christopher Viehbacher said in a statement. “Aduhelm was that groundbreaking discovery that paved the way for a new class of drugs and reinvigorated investments in the field.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Guidelines to prevent youth baseball injuries need more muscle
Next article： Microsoft launches AI tool for clinical documentation through Epic

leisure time

WSS

Devoted Health’s losses in Medicare Advantage persist

A pediatrician calls for Congress to pass the child tax credit deal

Microsoft launches AI tool for clinical documentation through Epic

Why CTE doesn’t keep Americans from enjoying the Super Bowl

Problems with a popular proposal to regulate AI in health care

Medicare Advantage plans can’t deny care with AI, CMS warns

hotspot

comprehensive

explore

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Maisha Meds is a PBM, but don't call it that

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

Unique patient identifier: Experts argue the benefits, pitfalls

Peter Hotez and the public health issue of online harassment

Mass General, Mayo Clinic look to monetize custom

Hepatitis C has a cure — but many Americans still lack access to it

The CDC's new social media misinformation war

Supreme Court strikes down use of affirmative action

Readout Newsletter: Amgen, Regeneron, BGI Group and more

hotspot

FDA endorses new sterilization method for medical devices

Flu vaccine reformulation won't be easy, manufacturers warn

Global cancer cases to surge 77% by 2050, WHO report says

Global cancer cases to surge 77% by 2050, WHO report says

Dana Farber says 6 studies to be retracted and 31 corrected

Johnson & Johnson sued for allegedly overpaying for workers' drugs

leisure time

hotspot

focus

explore